Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).

Overview

Epidemiological data show that the incidence of carcinoma, the most common cancer, is strongly linked to the age. Non Melanoma Skin Carcinomas (NMSCs) (the most frequent cancers in the elderly population) derive from keratinocytes of the basal layer of the epidermis, from differentiated keratinocytes of the more superficial layers or from stem cells of hair follicles. Unlike NMSCs, soft-tissue sarcomas, including those deriving from dermal fibroblasts, are very rare (less than 1% of all cancers). Our overall purpose is to decipher the molecular pathways activated during the aging of these tissues that may explain why they have a so different propensity to undergo a malignant transformation. Given that senescent cells accumulate in the dermis and epidermis with age, we will constitute two groups : "young skin" that we arbitrarily limit to the range ≥ 18 and ≤ 40 and "aged skin" ≥ 55.

Thus the main objective of our study is to search within 2 age groups (≥ 18 and ≤ 40 years and ≥ 55 years) the expression of senescence markers on healthy skin tissue.

Full Title of Study: “Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues Collected for Two Age Groups.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 16, 2019

Detailed Description

- Information and obtaining informed consent.

- Collection of clinical data.

- Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a sarcoma.

- Freezing samples of healthy skin tissue in liquid nitrogen within 10 minutes after collection.

- Transfer of the samples to the laboratory of anatomopathology.

- Preparation of the healthy skin samples by the laboratory of anatomopathology.

- Transfer of the conditioned samples to the Institut de Biologie de Lille for analysis.

- Control of the aesthetic appearance during the postoperative consultation.

- Destruction of the samples at the end of analysis.

Interventions

  • Procedure: Collection of healthy skin tissue
    • Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.

Arms, Groups and Cohorts

  • Experimental: Collection of healthy skin tissue
    • Collection of healthy skin tissue

Clinical Trial Outcome Measures

Primary Measures

  • Expression of senescence markers in healthy skin tissues collected for the two age groups.
    • Time Frame: Baseline

Secondary Measures

  • Research of emerging cells in the skin tissue of the subjects of the two age groups via the expression of the Protease-Activated Receptor-1 (PAR-1).
    • Time Frame: Baseline
  • Presence of different types of DNA damage (single and double strand breaks) in the keratinocytes and fibroblasts of the skin tissues of the two age groups.
    • Time Frame: Baseline
  • Morbidity
    • Time Frame: Baseline
    • Postoperative complications up to 30 days after surgery according to the Clavien-Dindo classification (2009), according to the NCI-CTCAE v4.0 beyond this deadline.

Participating in This Clinical Trial

Inclusion Criteria

  • Patient with an operable sarcoma
  • Requiring a surgical operation under general anesthesia at the Oscar Lambret Centre
  • Age ≥ 18 ans, belonging to one of the two following age groups : [ ≥ 18 and ≤ 40 years] and [ ≥ 55 years]
  • Patient having a social security scheme
  • Patient having signed an informed consent form for the study

Exclusion Criteria

  • Patient aged under 18 or between 41 and 54
  • Location of the tumor on the face, neck or neckline
  • Patient with a skin tumor
  • Tumor-induced cutaneous fistula making suspect a tumor invasion of the skin
  • Patient with a chronic skin disease
  • Collection in an area already treated by surgery, radiotherapy or brachytherapy
  • Pregnant or breastfeeding women
  • Patient under guardianship or tutorship

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Oscar Lambret
  • Collaborator
    • Institut de Biologie de Lille
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nicolas PENEL, MD, Study Chair, Centre Oscar Lambret
    • Olivier PLUQUET, Study Director, Institut de Biologie de Lille

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.